Trending Down-0.0246 (-8.6437%)
  • Bid / Lots
    0.2630/ 10
  • Ask / Lots
    0.2699/ 1
  • Open / Previous Close
    0.2800 / 0.2846
  • Day Range
    Low 0.2510
    High 0.2800
  • 52 Week Range
    Low 0.2510
    High 9.1109
  • Volume
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 0.2846
09:32 ET82000.27
09:42 ET270220.251
09:51 ET1090.255
09:55 ET3460.2572
10:00 ET9890.257499
10:04 ET1000.257499
10:06 ET12290.2551
10:15 ET53830.251
10:24 ET160000.27
10:29 ET136300.268275
10:36 ET1000.269799
10:40 ET110980.2525
10:42 ET4790.2699
10:45 ET1000.26245
11:25 ET14820.2625
11:30 ET60000.2601
11:32 ET60000.262399
11:34 ET11080.255
11:36 ET1000.2623
11:39 ET30000.255
11:45 ET1220.25865
12:08 ET10000.26
12:14 ET21000.2622
12:17 ET1000.2625
12:21 ET25000.2624
12:39 ET3000.2623
12:48 ET1000.26065
12:50 ET4180.2623
12:51 ET4500.2624
01:04 ET1000.2624
01:20 ET4500.2624
01:22 ET10000.262299
01:24 ET1000.2623
01:29 ET6000.2624
01:36 ET6000.2624
01:47 ET1000.2624
01:49 ET1000.2624
01:51 ET75000.2624
01:56 ET3450.261993
02:23 ET117820.26
02:27 ET1000.2599
02:34 ET24000.259975
02:39 ET3450.26
03:03 ET40000.259896
03:10 ET1000.2599
03:12 ET1000.2599
03:26 ET71280.2612
03:39 ET1283780.26
03:42 ET99000.2599
03:44 ET49810.2589
03:50 ET5000.261199
03:55 ET1000.2624
03:57 ET32440.26
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesVIRI
Virios Therapeutics Inc
United StatesBVXV
BiondVax Pharmaceuticals Ltd
United StatesRNAZ
Transcode Therapeutics Inc
United StatesCWBR
CohBar Inc
United StatesPHIO
Phio Pharmaceuticals Corp
United StatesCFRX
ContraFect Corp
As of 2022-12-07

Company Information

Virios Therapeutics, Inc. is a development-stage biotechnology company focused on advancing antiviral therapies to treat debilitating chronic diseases such as fibromyalgia (FM). The Company’s lead development candidate is IMC-1, which is a fixed dose combination of famciclovir, and celecoxib designed to synergistically suppress herpes virus replication. IMC-1 combines these two specific mechanisms of action purposely designed to inhibit herpes virus activation and replication. The Company’s pipeline product includes IMC-2 (valacyclovir and celecoxib), which is in the Phase 1 development stage. IMC-2 (valacyclovir and celecoxib) is developed for treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with Long-COVID or Post-Acute Sequelae of COVID-19 (PASC).

Contact Information

44 Milton AvenueALPHARETTA, GA, United States 30009


Chairman of the Board, Chief Executive Officer
Gregory Duncan
Founder, Director
William Pridgen
Senior Vice President - Finance
Angela Walsh
Senior Vice President of Operations
Ralph Grosswald
Chief Medical Officer
R. Michael Gendreau

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
Revenue (TTM)
Shares Outstanding
Dividend Yield
Annual Dividend Rate
Ex-Dividend Date
Pay Date
Book Value
P/E Ratio
Price/Sales (TTM)
Price/Cash Flow (TTM)
Operating Margin
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.